Cargando…
Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
Silicosis is the most prevalent and fatal occupational disease with no effective therapeutics, and currently used drugs cannot reverse the disease progress. Worse still, there are still challenges to be addressed to fully decipher the intricated pathogenesis. Thus, specifying the essential mechanism...
Autores principales: | Wang, Mingyao, Zhang, Zhe, Liu, Jiangfeng, Song, Meiyue, Zhang, Tiantian, Chen, Yiling, Hu, Huiyuan, Yang, Peiran, Li, Bolun, Song, Xiaomin, Pang, Junling, Xing, Yanjiang, Cao, Zhujie, Guo, Wenjun, Yang, Hao, Wang, Jing, Yang, Juntao, Wang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098425/ https://www.ncbi.nlm.nih.gov/pubmed/35551173 http://dx.doi.org/10.1038/s41392-022-00959-3 |
Ejemplares similares
-
Comparative Transcriptome Analyses Reveal a Transcriptional Landscape of Human Silicosis Lungs and Provide Potential Strategies for Silicosis Treatment
por: Pang, Junling, et al.
Publicado: (2021) -
Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series
por: Hughes, David M., et al.
Publicado: (2021) -
Multi-omics study of silicosis reveals the potential therapeutic targets PGD(2) and TXA(2)
por: Pang, Junling, et al.
Publicado: (2021) -
Single-Cell Transcriptome Profiles Reveal Fibrocytes as Potential Targets of Cell Therapies for Abdominal Aortic Aneurysm
por: Li, Bolun, et al.
Publicado: (2021) -
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)